Navigation Links
Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
Date:9/19/2007

of action that inhibits growth and targets both sporulation and toxin production, REP3123 could be a future treatment option that tackles the main challenges associated with treating CDAD: high rates of relapse and new outbreaks," stated Kenneth J. Collins, Replidyne's President & CEO. "We are excited by the potential of REP3123 and look forward to its further development."

About Clostridium difficile

C. difficile is a Gram-positive anaerobic bacterium that causes C. difficile-associated disease (CDAD). According to the Centers for Disease Control and Prevention, CDAD is on the rise worldwide, both in terms of number of cases and severity of the disease. Most cases of CDAD occur in a hospital setting due to increased use of antibiotics and other chemotherapeutics that disrupt normal intestinal flora, an ageing population, and difficulty of eradicating C. difficile spores. However, more recently, CDAD has been acquired in the community setting where several outbreaks with increased mortality have occurred. The emergence of an epidemic, hypervirulent C. difficile strain (BI/NAP1, 027) that produces high levels of toxins poses a real threat to public health and demands improved infection control as well as novel treatment options.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and related dis
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... ROSH HA,AYIN, Israel, December 15 ... for the advanced chronic,wound management market, announced ... U.S. Food and Drug Administration (FDA) to ... The FDA also cleared,DermaSept, an Over-the-Counter version ... EnzySurge is the developer of ...
(Date:12/15/2009)... At today,s regular meeting of the board of directors ... the board declared a regular quarterly dividend of 31 ... of record at the close of business on February ... ,, The Lubrizol Corporation (NYSE: LZ ) ... supplies technologies that improve the quality and performance of ...
(Date:12/15/2009)... Medical, Inc. (Nasdaq: NXTM ), a leading ... a group of its home hemodialysis patients and ... conventional (non-dialysis) Caribbean cruise with their NxStage® System ... Freedom Cruise: We,re Taking Home Dialysis to Sea," ... and returns on January 10, 2010. The ...
Breaking Medicine Technology:EnzySurge Receives FDA Approval for SilverStream(TM) Innovative Wound Management Solution 2Lubrizol Declares Dividend 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 2Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 3Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM) 4Vermillion Files Plan of Reorganization 6521 1Vermillion Files Plan of Reorganization 6521 2Vermillion Files Plan of Reorganization 6521 3French Ambassador for International Investment to Visit Chicago December 9 and 10 14972 1Researchers Identify Possible Causative Mutation for Crohn 26apos 3Bs Disease 3A Crohn 26apos 3Bs 26amp 3B Colitis Foundation Annual Conference to Pr 62072 1Researchers Identify Possible Causative Mutation for Crohn 26apos 3Bs Disease 3A Crohn 26apos 3Bs 26amp 3B Colitis Foundation Annual Conference to Pr 62072 2Researchers Identify Possible Causative Mutation for Crohn 26apos 3Bs Disease 3A Crohn 26apos 3Bs 26amp 3B Colitis Foundation Annual Conference to Pr 62072 3Researchers Identify Possible Causative Mutation for Crohn 26apos 3Bs Disease 3A Crohn 26apos 3Bs 26amp 3B Colitis Foundation Annual Conference to Pr 62072 4
... PALO ALTO, Calif., April 17, 2007 /PRNewswire-FirstCall/ ... results from a,Phase 2 clinical trial of ... carboplatin and paclitaxel in the,first-line treatment of ... highly statistically and clinically significant,improvement in both ...
... Blood Highlight Millennium Leadership in,Personalized Medicine and Could ... in Broad Range of Multiple Myeloma Patients -, ... in the April 15th issue of Blood show ... Inc. has,discovered biomarkers which may lead to identifying ...
Other Medicine Technology:Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 2Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 3Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 4Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 5Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 6
(Date:12/16/2009)... for the Christmas rush Hallmark Cards have announced a great ... industry. With an easy to navigate website at www.hallmark.co.uk/specialoccasions , ... you with their own words and photos and then order as ... , ... Bradford, UK (PRWEB) December 16, 2009 -- Just ...
(Date:12/16/2009)... rapidly approaching and what would be the perfect gift to give ... course! Celebrity Beauty Engineer® and Licensed Esthetician Mary Schook introduces exceptional ... and feel their best! , ... (PRWEB) December 16, ... gift does a person get that special woman who has everything? ...
(Date:12/16/2009)... your loved ones this holiday season, give them the gift of ... child care, and pet care through Delegate Source. , ... ... Denver and Boulder metro areas have the opportunity to give a ... using Delegate Source,s " Give a Gift " program to provide ...
(Date:12/15/2009)... 15 The failure of the U.S. ... cut costs, much less the more effective direct ... latest example of how big industry controls the ... proposed drug amendment by Senator Dorgan (D-ND) was ... campaign pledge to allow Medicare to directly negotiate ...
(Date:12/15/2009)... Calls For Preserving State Authority, Ban on Annual ... WASHINGTON, Dec. 15 Consumer Watchdog condemned ... those over 55 and the public option from ... group said that the Senate must still make ... to prevent ceding the entire health care system ...
Breaking Medicine News(10 mins):Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 2Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 3Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 4Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2Health News:Give the Gift of Service This Holiday Season with Delegate Source 2Health News:Give the Gift of Service This Holiday Season with Delegate Source 3Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5
... HOPKINTON, Mass., May 29 Alseres,Pharmaceuticals, Inc. (Nasdaq: ... will,hold its Annual Meeting of Stockholders Thursday, June ... of Wilmer Cutler Pickering Hale & Dorr, 60 ... ), About Alseres Pharmaceuticals, Inc., Alseres ...
... major cause of hyperactivity in children. Genetics, brain function and ... , A review of scientific evidence ... what they eat. A combination of food, genetics and environmental ... factor to blame. , Foods which might affect behaviour, ...
... practice provides comfort and nutrition , , THURSDAY, May 29 ... provide women with the energy they need and should ... from the American College of Nurse-Midwives. , "It,s important ... eat or drink during labor. In addition to providing ...
... This release is available in German . ... patients suffer from poorly healing large-area wounds caused by ... be treated with conventional collagen dressings or polylactic acid dressings, ... should be. A new type of dressing made of silica ...
... and Site Survey Products to Support New Wi-Fi ... Inc., a leading,provider of Wi-Fi-based Real Time Location ... tracking solution and Ekahau Site Survey,(ESS) Wi-Fi network ... upcoming 802.11n standard., Enterprises are already embracing ...
... Cynthia Nixon, Gabrielle Union, Ricardo Chavira, Vanessa Carlton to ... Raise Awareness, Funds for Global Breast Cancer Leader, ... Nixon, Gabrielle Union, Ricardo Chavira and,Vanessa Carlton will join ... nation next week for events and activities leading up ...
Other Medicine News:Health News:Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting 2Health News:Children's diet not the main cause of ADHD 2Health News:Clinical Guideline Backs Food, Drink During Labor 2Health News:Rapid wound healing 2Health News:Ekahau Announces Compatibility With 802.11n 2Health News:Ekahau Announces Compatibility With 802.11n 3Health News:Susan G. Komen for the Cure(R) Celebrity Ambassadors to Convene in Nation's Capital to Help Race for the Cure, End Breast Cancer Forever 2
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Medicine Products: